Osimertinib, also known as Tagrisso, is a revolutionary medication designed to treat lung cancer, specifically non-small cell lung cancer (NSCLC). This targeted therapy works by blocking the activity of a protein called EGFR, which is often mutated in lung cancer cells. By inhibiting this protein, osimertinib helps to slow down the growth and spread of cancer cells, offering hope to patients...

Osimertinib, also known as Tagrisso, is a targeted cancer therapy medication primarily used for the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs) and is specifically designed to target and inhibit the activity of the EGFR (epidermal growth factor receptor) protein, which is often overexpressed in NSCLC patients. This...

Osimertinib, also known as Tagrisso, is a revolutionary targeted therapy for cancer patients, specifically those with non-small cell lung cancer (NSCLC). This medication works by inhibiting the tyrosine kinase activity of the EGFR (epidermal growth factor receptor) and c-Met proteins, which are known to promote the growth and spread of cancer cells. Osimertinib has gained significant attention...